Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
Go back to Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 8.55 +0.55 (6.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.00 | 52 Week High | $7.27 | |||
| Open | $7.91 | 52 Week Low | $2.39 | |||
| Day High | $8.69 | P/E | N/A | |||
| Day Low | $7.91 | EPS | $-0.61 | |||
| Volume | 4,223,005 | |||||
